49. 全身性エリテマトーデス Systemic lupus erythematosus Clinical trials / Disease details


臨床試験数 : 946 薬物数 : 722 - (DrugBank : 186) / 標的遺伝子数 : 117 - 標的パスウェイ数 : 199

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2007-004635-29-DK
(EUCTR)
09/11/200702/10/2007Randomised, placebo controlled, international multi-centre, double blind, dose confirmation study testing the safety and efficacy of ASF-1096 cream 0.25%, 0.5% and 1% and placebo applied twice daily in the treatment of cutaneous lupus erythematosus lesions - ASF-1096-301Randomised, placebo controlled, international multi-centre, double blind, dose confirmation study testing the safety and efficacy of ASF-1096 cream 0.25%, 0.5% and 1% and placebo applied twice daily in the treatment of cutaneous lupus erythematosus lesions - ASF-1096-301 Patients with Discoid Lupus Erythematosus (DLE) or Subacute Cutaneous Lupus Erythematosus (SCLE) symptoms of the skin can be included in this study. Those patients who have a diagnosis of Systemic Lupus Erythematosus (SLE) with DLE or SCLE lesions of the skin can also be included in the study.Product Name: ASF-1096 Cream 0.25%
INN or Proposed INN: R-salbutamol sulphate
Product Name: ASF-1096 Cream 0.5%
INN or Proposed INN: R-salbutamol sulphate
Product Name: ASF-1096 Cream 1.0%
INN or Proposed INN: R-salbutamol sulphate
Astion Pharma A/SNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
140Denmark;Spain;Sweden
2EUCTR2007-004635-29-SE
(EUCTR)
07/11/200712/09/2007Randomised, placebo controlled, international multi-centre, double blind, dose confirmation study testing the safety and efficacy of ASF-1096 cream 0.25%, 0.5% and 1% and placebo applied twice daily in the treatment of cutaneous lupus erythematosus lesions - ASF-1096-301Randomised, placebo controlled, international multi-centre, double blind, dose confirmation study testing the safety and efficacy of ASF-1096 cream 0.25%, 0.5% and 1% and placebo applied twice daily in the treatment of cutaneous lupus erythematosus lesions - ASF-1096-301 Patients with Discoid Lupus Erythematosus (DLE) or Subacute Cutaneous Lupus Erythematosus (SCLE) symptoms of the skin can be included in this study. Those patients who have a diagnosis of Systemic Lupus Erythematosus (SLE) with DLE or SCLE lesions of the skin can also be included in the study.Product Name: ASF-1096 Cream 0.25%
INN or Proposed INN: R-salbutamol sulphate
Product Name: ASF-1096 Cream 0.5%
INN or Proposed INN: R-salbutamol sulphate
Product Name: ASF-1096 Cream 1.0%
INN or Proposed INN: R-salbutamol sulphate
Astion Pharma A/SNULLNot RecruitingFemale: yes
Male: yes
140Denmark;Spain;Sweden
3EUCTR2006-001062-17-SE
(EUCTR)
07/03/200712/01/2007Efficacy and safety of ASF-1096 Cream 0.5% in the treatment of patients with newly developed discoid lupus erythematosus (DLE) lesions. A multi centre clinical phase 2, placebo controlled and double blind proof of concept study. - Lupus studyEfficacy and safety of ASF-1096 Cream 0.5% in the treatment of patients with newly developed discoid lupus erythematosus (DLE) lesions. A multi centre clinical phase 2, placebo controlled and double blind proof of concept study. - Lupus study Male or female patients with a clinical diagnosis of either Discoid Lupus Erythematosus or Systemic Lupus Erythematosus and at least one newly developed, sharply demarcated DLE lesion.
MedDRA version: 8.1;Level: LLT;Classification code 10025138;Term:
Product Name: ASF-1096 Cream 0.5%Astion Danmark A/SNULLNot RecruitingFemale: yes
Male: yes
52Phase 2United Kingdom;Sweden